Drug
Botulinum Antitoxin Heptavalent
Botulinum Antitoxin Heptavalent: highest development phase Phase 1, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) NCT00360737 | Phase 1 | Healthy |
Latest
No recent events.
Follow Botulinum Antitoxin Heptavalent on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.